Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
Figure 2
Survival of patients achieving an antileukemic effect or stable response compared with that of patients showing disease progression. Patients for whom an anti-leukemic effect was observed had a mean duration of survival that doubled the one of those with a bortezomib fully insensitive disease (4 months versus 2 months; ).